Atrion Co. (ATRI) Shares Bought by Morgan Stanley

Morgan Stanley lifted its holdings in shares of Atrion Co. (NASDAQ:ATRI) by 198.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 12,532 shares of the medical instruments supplier’s stock after purchasing an additional 8,328 shares during the period. Morgan Stanley owned 0.68% of Atrion worth $8,707,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in ATRI. Schroder Investment Management Group grew its holdings in shares of Atrion by 11.7% in the second quarter. Schroder Investment Management Group now owns 1,033 shares of the medical instruments supplier’s stock valued at $619,000 after purchasing an additional 108 shares in the last quarter. Aperio Group LLC grew its holdings in shares of Atrion by 23.6% in the third quarter. Aperio Group LLC now owns 1,703 shares of the medical instruments supplier’s stock valued at $1,183,000 after purchasing an additional 325 shares in the last quarter. Cornerstone Wealth Management LLC grew its holdings in shares of Atrion by 21.6% in the third quarter. Cornerstone Wealth Management LLC now owns 65,995 shares of the medical instruments supplier’s stock valued at $100,000 after purchasing an additional 11,743 shares in the last quarter. First Trust Advisors LP grew its holdings in shares of Atrion by 279.4% in the third quarter. First Trust Advisors LP now owns 5,034 shares of the medical instruments supplier’s stock valued at $3,498,000 after purchasing an additional 3,707 shares in the last quarter. Finally, Assenagon Asset Management S.A. acquired a new position in shares of Atrion in the third quarter valued at approximately $4,172,000. Institutional investors own 63.75% of the company’s stock.

NASDAQ ATRI opened at $786.14 on Tuesday. Atrion Co. has a 52 week low of $516.85 and a 52 week high of $803.00. The company has a market cap of $1.47 billion, a price-to-earnings ratio of 41.95 and a beta of 0.45.

Atrion (NASDAQ:ATRI) last posted its quarterly earnings results on Friday, November 9th. The medical instruments supplier reported $4.96 EPS for the quarter. Atrion had a net margin of 23.19% and a return on equity of 18.01%. The company had revenue of $39.27 million during the quarter.

In other Atrion news, CFO Jeffery Strickland sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 28th. The shares were sold at an average price of $768.07, for a total transaction of $1,536,140.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 22.46% of the company’s stock.

ATRI has been the subject of a number of research reports. BidaskClub cut shares of Atrion from a “buy” rating to a “hold” rating in a report on Friday, November 2nd. ValuEngine upgraded shares of Atrion from a “hold” rating to a “buy” rating in a report on Monday, February 4th.

TRADEMARK VIOLATION NOTICE: “Atrion Co. (ATRI) Shares Bought by Morgan Stanley” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2019/02/12/atrion-co-atri-shares-bought-by-morgan-stanley.html.

Atrion Company Profile

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

See Also: How to interpret the current ratio

Institutional Ownership by Quarter for Atrion (NASDAQ:ATRI)

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply